Novel DNA Test Evaluates Recurrent Pregnancy Loss
By LabMedica International staff writers Posted on 03 Apr 2014 |
Image: The Qubit Quantitation Fluorometer platform quantifies DNA, RNA, and protein (Photo courtesy of Life technologies).
The alternative DNA test offers clinically relevant genetic information to identify why a miscarriage may have occurred years earlier and it is possible to identify chromosomal variants and abnormalities in nearly 50% of the samples.
The technique is called rescue karyotyping, and allows physicians to obtain important genetic information from tissue that had not been tested at the time of the miscarriage. As part of standard hospital protocol, tissue from miscarriages is embedded in paraffin for archival use and the karyotyping test is performed on DNA extracted from this tissue.
Scientists from the Albert Einstein College of Medicine (Bronx, NY, USA) carried out a retrospective study of 20 samples from 17 women, and genetic testing was successfully performed on 16 samples that had been archived for as long as four years. A slide from the formalin-fixed paraffin-embedded (FFPE) block was reviewed by a pathologist and the area of fetal tissue circled. Fetal or chorionic villus cells were macro-dissected from this circled area to reduce maternal cell contamination (MCC) and subjected to DNA extraction.
The genomic DNA (gDNA) concentration was measured using Nanodrop 1000 (Thermo Fisher Scientific; Waltham, MA, USA) and quantified by Qubit 2.0 Fluorometer (Life Technologies; Carlsbad, CA, USA). Array-based comparative genomic hybridizations (aCGH) were run on Agilent CGH arrays (Agilent Technologies; Santa Clara, CA, USA) for high resolution testing. Of the 16 specimens that had sufficient DNA for aCGH analysis, 8 (50.0%) were euploid, and 8 (50.0%) showed copy number variants potentially responsible for the pregnancy loss. When conventional karyotyping testing is unavailable for any reason, rescue karyotyping provides a critical alternative method to uncover the genomic information.
Zev Williams, MD, PhD, an assistant professor of obstetrics and gynecology and lead author of the study said, “Given the ease of obtaining results, even if a delay in testing occurs, this new test may provide a useful technique to gain a better understanding as to why miscarriage occurs in some women. I have seen women in tears because testing was not done at the time of the miscarriage and they feared they would never learn why it happened. Now we are able to go back and often get the answers we need.” The study was published on March 3, 2014, in the journal Reproductive Biology and Endocrinology.
Related Links:
Albert Einstein College of Medicine
Thermo Fisher Scientific
Life Technologies
The technique is called rescue karyotyping, and allows physicians to obtain important genetic information from tissue that had not been tested at the time of the miscarriage. As part of standard hospital protocol, tissue from miscarriages is embedded in paraffin for archival use and the karyotyping test is performed on DNA extracted from this tissue.
Scientists from the Albert Einstein College of Medicine (Bronx, NY, USA) carried out a retrospective study of 20 samples from 17 women, and genetic testing was successfully performed on 16 samples that had been archived for as long as four years. A slide from the formalin-fixed paraffin-embedded (FFPE) block was reviewed by a pathologist and the area of fetal tissue circled. Fetal or chorionic villus cells were macro-dissected from this circled area to reduce maternal cell contamination (MCC) and subjected to DNA extraction.
The genomic DNA (gDNA) concentration was measured using Nanodrop 1000 (Thermo Fisher Scientific; Waltham, MA, USA) and quantified by Qubit 2.0 Fluorometer (Life Technologies; Carlsbad, CA, USA). Array-based comparative genomic hybridizations (aCGH) were run on Agilent CGH arrays (Agilent Technologies; Santa Clara, CA, USA) for high resolution testing. Of the 16 specimens that had sufficient DNA for aCGH analysis, 8 (50.0%) were euploid, and 8 (50.0%) showed copy number variants potentially responsible for the pregnancy loss. When conventional karyotyping testing is unavailable for any reason, rescue karyotyping provides a critical alternative method to uncover the genomic information.
Zev Williams, MD, PhD, an assistant professor of obstetrics and gynecology and lead author of the study said, “Given the ease of obtaining results, even if a delay in testing occurs, this new test may provide a useful technique to gain a better understanding as to why miscarriage occurs in some women. I have seen women in tears because testing was not done at the time of the miscarriage and they feared they would never learn why it happened. Now we are able to go back and often get the answers we need.” The study was published on March 3, 2014, in the journal Reproductive Biology and Endocrinology.
Related Links:
Albert Einstein College of Medicine
Thermo Fisher Scientific
Life Technologies
Latest Molecular Diagnostics News
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety